PET imaging can evaluate the pharmacokinetics, tumor targeting efficacy, and dose optimization of ATN-291, preparing it for future uPA-targeted cancer therapy, patient screening, and image-guided tumor surgery in clinics. This evidence concerns the gene PLAU and cancer.